The Enduring Success of Hybridoma-based Antibody Development
White Paper Aug 14, 2019

Since its original development in 1975, hybridoma technology encourages researchers all over the world to share their antibodies with one another, unlocking a vast amount of potential for biological research.
Due to their high selectivity, monoclonal antibodies (mAbs) are used in a wide range of disciplines, including research, diagnostics and therapeutic applications. Despite the advancement of modern antibody generation technologies, hybridoma-based antibody production continues to be a leading approach for mAb discovery and development.
Download these whitepapers to explore:
- The key benefits of using hybridoma-based antibody development
- Perceived misconceptions relating to hybridoma technology
- Alternative approaches that currently exist for mAb generation
Related White Papers
Download this white paper to find out how rabbit mAbs can be reliably generated with the upgraded MonoRab™ platform.
READ MOREDownload this whitepaper to find out how you can advance your host cell protein analysis.
READ MOREDownload this whitepaper to find out how InCellis® can enhance your confluency measurements.
READ MORELike what you just read? You can find similar content on the communities below.
Cell Science Drug Discovery Immunology & MicrobiologyTo personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREE